ROBERTS BRIAN KENNETH

CMO Brian Roberts bought 28,000 RZLT shares at $1.70 on 2025-12-16 (+10.0% of holdings); stock down 81.6% from 52-week high amid cluster buy

Chief Medical Officer Brian Roberts purchased 28,000 shares at $1.70, raising his holdings to 308,352 shares post-transaction. His prior 5 buys at RZLT exhibited a 100% win rate at the 90-day mark, with returns of +44.0%, +33.5%, +31.5%, +33.6%, and +31.8%, suggesting consistent timing accuracy in this stock. However, the current price of $2.01 reflects severe compression—down 81.6% from the 52-week high of $10.94 and down 80.3% over the past 30 days—amid fundamentals showing $-18.2M net income. The timing of this buy alongside 4 other insiders' purchases within 14 days creates a cluster pattern that may indicate management's view of valuation at depressed levels, though the company remains unprofitable.

CMO Roberts buys 2,500 RZLT shares at $4.38; 5th buy in 12 months, all well-timed at 90d mark; cluster of 4 insiders buying within 14 days

Roberts purchased 2,500 shares at $4.38, expanding his holdings by 19.2% from 13,000 to 15,500 shares. This is his fifth open-market purchase of RZLT in the past year, and each prior buy at this ticker generated positive 90-day returns (ranging 31.5% to 59.9%), establishing a pattern of well-timed entry points. The broader context shows three additional insiders acquiring shares within the past 14 days, indicating coordinated insider confidence. However, Rezolute remains unprofitable with a net loss of $18,914,000 for the most recent full fiscal year, so the fundamental backdrop remains challenged; the cluster-buy signal must be weighed against ongoing operational losses and a stock trading 27.7% below its 52-week high despite recent momentum (30-day gain of 12.5%).

CMO Roberts purchases 7,600 shares in 4 transactions at blended avg $3.91 on 2024-06-14, continuing recent buying pattern at RZLT

Brian Kenneth Roberts, Chief Medical Officer, executed 4 separate purchases totaling 7,600 shares for $29,743.17 at a blended average price of $3.91 on 2024-06-14. This continues an active accumulation pattern at Rezolute: Roberts has made 5 prior purchases at this ticker since March 2024, with his two earliest measurable outcomes both showing strong 90-day returns (+191.5% and +213.0%). The current stock price of $3.95 is approximately at the transaction price, representing a +49.1% gain over 30 days and +121.9% over 90 days. However, the company remains unprofitable with net income of $-17,050,000.00, and Roberts' post-transaction holdings of 1,376 shares suggest he is building a modest position. His cross-ticker track record shows 9 prior buys with an 83.33% 90-day win rate and average 90-day return of +110.1%, indicating a historically accurate buyer at multiple companies, though this specific ticker's sustainability remains unproven given the negative fundamentals.